Hemolytic disease of the newborn caused by anti-U: A case report

Article Sidebar

Global Journal of Medical and Clinical Case Reports volume7-issue1 articles
PDF HTML
Submitted: March 19, 2020
Published: Apr 16, 2020
DOI: 10.17352/2455-5282.000080
Keywords:
Alloimmunization, Hemolytic disease of the newborn, Direct antiglobulin test

Main Article Content

Renata Esteves Almeida
MD, Transfusion Agency-Herculano Pinheiro Maternity Hospital, Rio de Janeiro, Brazil
Sandro Artur Fierz
MD, PhD, Blood Bank-University Hospital, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Flavia Miranda Constantino-Bandeira
MD, PhD, Blood Bank-University Hospital, State University of Rio de Janeiro, Rio de Janeiro, Brazil
Patricia Olga Souza-Sergio
MD, Ambulatory of Perinatal Hemolytic Disease-Martagão Gesteira Institute of Childcare and Pediatrics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Cristiane Sá Ferreira Facio
MD, Ambulatory of Perinatal Hemolytic Disease-Martagão Gesteira Institute of Childcare and Pediatrics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Alexandre Gomes Vizzoni*
PhD, Transfusion Agency-Evandro Chagas National Institute of Infectious Diseases, Rio de Janeiro, Brazil

Abstract

Maternal red blood cell alloimmunization is an important cause of morbidity and mortality in the antepartum and neonatal periods. Typically, the serological diagnosis of Hemolytic Disease of the Fetus and Newborn (HDFN) includes a positive direct antiglobulin test on the infant’s red blood cells and the presence of an IgG red cell alloantibody in both maternal and cord sera.

Downloads

Download data is not yet available.

Article Details

Almeida, R. E., Fierz, S. A., Constantino-Bandeira, F. M., Souza-Sergio, P. O., Facio, C. S. F., & Gomes Vizzoni, A. (2020). Hemolytic disease of the newborn caused by anti-U: A case report. Global Journal of Medical and Clinical Case Reports, 7(1), 010–012. https://doi.org/10.17352/2455-5282.000080
Case Reports

Copyright (c) 2020 Almeida RE, et al.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Xie X, Fu Q, Bao Z, Zhang Y, Zhou D (2020) Clinical value of different anti-D immunoglobulin strategies for preventing Rh hemolytic disease of the fetus and newborn: A network meta-analysis. PLoS One 15: e0230073. Link: https://bit.ly/2yddO5c

Koelewijn JM, Slootweg YM, Folman C, van Kamp IL, Oepkes D, et al. (2020) Diagnostic value of laboratory monitoring to predict severe hemolytic disease of the fetus and newborn in non-D and non-K-alloimmunized pregnancies. Transfusion 60: 391-399. Link: https://bit.ly/2ygOEmd

Moinuddin I, Fletcher C, Millward P (2019) Prevalence and specificity of clinically significant red cell alloantibodies in pregnant women - a study from a tertiary care hospital in Southeast Michigan. J Blood Med 10: 283-289. Link: https://bit.ly/2XAVzRB

Win N, Almusawy M, Fitzgerald L, Hannah G, Bullock T (2019) Prevention of hemolytic transfusion reactions with intravenous immunoglobulin prophylaxis in U– patients with anti-U. Transfusion 59: 1916-1920. Link: https://bit.ly/3abBGmI

Adam S, Lombaard H (2016) Autologous intrauterine transfusion in a case of anti-U. Transfusion 56: 3029-3032. Link: https://bit.ly/34Bcjts

Moosavi M, Ma Y, Baez J, Jeffreys R, Ward DC, et al. (2020) Resolving Blocked Antigen Phenomenon in Hemolytic Disease of the Fetus and Newborn Due to Anti-K. Transfus Med Rev pii: S0887-7963(20)30013-4. Link: https://bit.ly/2V9wjjJ

Santos FLS, Cuter TB, Rodrigues ES, Bettarello ÊC, Ubiali EMA, et al. (2019) Molecular analysis of the rare S–s– red blood cell phenotype in blood donors and patients in south-east Brazil. Vox Sang 114: 262-267. Link: https://bit.ly/2K61p5N